Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

EPA Transcriptomic Assessment Product (ETAP) for Perfluoro-3-Methoxypropanoic Acid

ABSTRACT: The EPA Transcriptomic Assessment Product (ETAP) is a human health assessment that utilizes a standardized short-term in vivo study design and data analysis procedures to develop transcriptomic-based reference values for data poor chemicals. The reference value represents the daily dose of the chemical that would likely be without appreciable risk to human health over a lifetime. This dataset corresponds to the transcriptomic studies on perfluoro-3-methoxypropanoic acid (DTXSID70191136). More information about ETAP is available at: https://www.epa.gov/etap

ORGANISM(S): Rattus norvegicus

PROVIDER: GSE260875 | GEO | 2024/03/05

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

EPA Transcriptomic Assessment Product (ETAP) for Perflurohexanesulfonamide

Project description:The EPA Transcriptomic Assessment Product (ETAP) utilizes a standardized short-term in vivo study design and data analysis procedures to develop transcriptomic-based reference values for data poor chemicals. This data set corresponds to a report following the ETAP standard methods to derive a transcriptomic point of departure for Perflurohexanesulfonamide (PFHxSA). More information about the ETAP program is available here: https://www.epa.gov/etap

2025-06-26 | GSE285856 | GEO

EPA Transcriptomic Assessment Product (ETAP) for 7:3 Fluorotelomer alcohol

Project description:The EPA Transcriptomic Assessment Product (ETAP) utilizes a standardized short-term in vivo study design and data analysis procedures to develop transcriptomic-based reference values for data poor chemicals. This data set corresponds to a report following the ETAP standard methods to derive a transcriptomic point of departure for 7:3 Fluorotelomer alcohol (7:3 FTOH). More information about the ETAP program is available here: https://www.epa.gov/etap

2025-06-26 | GSE293924 | GEO

EPA Transcriptomic Assessment Product (ETAP) for 3:3 Fluorotelomer carboxylic acid

Project description:The EPA Transcriptomic Assessment Product (ETAP) utilizes a standardized short-term in vivo study design and data analysis procedures to develop transcriptomic-based reference values for data poor chemicals. This data set corresponds to a report following the ETAP standard methods to derive a transcriptomic point of departure for 3:3 Fluorotelomer carboxylic acid (3:3 FTCA). More information about the ETAP program is available here: https://www.epa.gov/etap

2025-06-26 | GSE286156 | GEO

EPA Transcriptomic Assessment Product (ETAP) for Perflurohexanesulfonamide

Project description:EPA Transcriptomic Assessment Product (ETAP) for Perflurohexanesulfonamide

| PRJNA1206224 | ENA

EPA Transcriptomic Assessment Product (ETAP) for 7:3 Fluorotelomer alcohol

Project description:EPA Transcriptomic Assessment Product (ETAP) for 7:3 Fluorotelomer alcohol

| PRJNA1247444 | ENA

EPA Transcriptomic Assessment Product (ETAP) for Perfluoro-3-Methoxypropanoic Acid

Project description:EPA Transcriptomic Assessment Product (ETAP) for Perfluoro-3-Methoxypropanoic Acid

| PRJNA1083898 | ENA

EPA Transcriptomic Assessment Product (ETAP) for 3:3 Fluorotelomer carboxylic acid

Project description:EPA Transcriptomic Assessment Product (ETAP) for 3:3 Fluorotelomer carboxylic acid

| PRJNA1208010 | ENA

EPA Campylobacter

Project description:EPA Campylobacter

| PRJEB67369 | ENA

Gene expression in colorectal liver metastasis tissues from EPA-treated patients

Project description:Eicosapentaenoic acid in its free fatty acid form (EPA-FFA), 2g daily, is safe and well-tolerated in patients undergoing liver resection surgery for colorectal liver metastasis.Oral EPA incorporates into colorectal liver metastasis tissue. EPA-FFA treatment is associated with reduced vascularity of liver metastases in ω-3 PUFA-naïve patients. Preoperative (median 30 days) EPA-FFA treatment may have prolonged benefit on postoperative overall and disease-free survival. We used whole genome expression array to study whether systemic CCL2 level changes were linked to a specific tumour gene expression profile in colorectal liver metastasis patients treated with EPA-FFA.

2016-03-16 | GSE79266 | GEO

The transcriptome profile in skeletal muscle of young male mice and aging male mice fed with or without eicosapentaenoic acid (EPA)

Project description:Age-related sarcopenia is associated with a variety of changes in skeletal muscle. These changes are interrelated with each other and associated with systemic metabolism, the details of which, however, are largely unknown. Eicosapentaenoic acid (EPA) is a promising nutrient against sarcopenia and has multifaceted effects on systemic metabolism. Although several human studies have suggested that EPA supplementation protects against sarcopenia, the causal relationship of EPA supplementation and an increase of muscle strength has poor evidence in vivo. We demonstrated that aging skeletal muscle in male mice shows lower grip strength and fiber type changes, both of which can be inhibited by EPA supplementation irrespective of muscle mass alteration. We hypothesized that the aging process in skeletal muscle can be intervened by the administration of EPA, via transcriptomic changes in skeletal muscle. This analysis revealed fast-to-slow fiber type transition in aging muscle, which was partially inhibited by EPA.

2020-12-21 | GSE149307 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data